Find Drugs in Development News & Deals for Roluperidone

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 359625-79-9, Cyr-101, Min-101, Min-101 free base, 4p31i0m3bf, 2-((1-(2-(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one
Molecular Formula
C22H23FN2O2
Molecular Weight
366.4  g/mol
InChI Key
RNRYULFRLCBRQS-UHFFFAOYSA-N
FDA UNII
4P31I0M3BF

Roluperidone
Roluperidone has been used in trials studying the treatment of Schizophrenia.
1 2D Structure

Roluperidone

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-[[1-[2-(4-fluorophenyl)-2-oxoethyl]piperidin-4-yl]methyl]-3H-isoindol-1-one
2.1.2 InChI
InChI=1S/C22H23FN2O2/c23-19-7-5-17(6-8-19)21(26)15-24-11-9-16(10-12-24)13-25-14-18-3-1-2-4-20(18)22(25)27/h1-8,16H,9-15H2
2.1.3 InChI Key
RNRYULFRLCBRQS-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1CN(CCC1CN2CC3=CC=CC=C3C2=O)CC(=O)C4=CC=C(C=C4)F
2.2 Other Identifiers
2.2.1 UNII
4P31I0M3BF
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Min-101

2. Roluperidone Hydrochloride

2.3.2 Depositor-Supplied Synonyms

1. 359625-79-9

2. Cyr-101

3. Min-101

4. Min-101 Free Base

5. 4p31i0m3bf

6. 2-((1-(2-(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one

7. Roluperidone (usan)

8. Roluperidone [usan]

9. 1h-isoindol-1-one, 2-((1-(2-(4-fluorophenyl)-2-oxoethyl)-4-piperidinyl)methyl)-2,3-dihydro-

10. Unii-4p31i0m3bf

11. Roluperidon

12. 2-((1-(2-(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)-2,3-dihydro-1h-isoindol-1-one

13. 2-({1-[2-(4-fluorophenyl)-2-oxoethyl]piperidin-4-yl}methyl)-2,3-dihydro-1h-isoindol-1-one

14. Cyr-101(roluperidone)

15. Roluperidone; Cyr-101

16. Roluperidone [inn]

17. Schembl5252391

18. Chembl4297605

19. Dtxsid10189512

20. Mt-210cyr-101

21. Ex-a3145

22. Mfcd28502826

23. Akos037643756

24. Cs-6971

25. Db13080

26. As-35144

27. Hy-19469

28. Db-086934

29. D11258

30. A1-49962

31. Q25100536

32. 2-[[1-[2-(4-fluorophenyl)-2-oxoethyl]piperidin-4-yl]methyl]-3h-isoindol-1-one

33. 2-({1-[2-(4-fluorophenyl)-2-oxoethyl]piperidin-4-yl}methyl)-2,3-dihydro-1h-isoindol-1-one; Min-101

34. 2-[[1-[2-(4-fluorophenyl)-2-oxoethyl]-4-piperidinyl]methyl]-2,3-dihydro-1h-isoindol-1-one

35. Yt7

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 366.4 g/mol
Molecular Formula C22H23FN2O2
XLogP33.2
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count4
Rotatable Bond Count5
Exact Mass366.17435614 g/mol
Monoisotopic Mass366.17435614 g/mol
Topological Polar Surface Area40.6 Ų
Heavy Atom Count27
Formal Charge0
Complexity538
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty